TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Ascelia Pharma AB ( (SE:ACE) ) is now available.
Ascelia Pharma’s Board of Directors has decided to convert 53,335 series C shares into ordinary shares to fulfill obligations under a performance-based share saving program. This conversion is part of the company’s long-term incentive program, with shares allocated to the CEO and other participants, maintaining the total number of outstanding shares at 127,902,580. This move reflects Ascelia Pharma’s commitment to incentivizing key personnel, potentially enhancing its strategic positioning in the biotech industry.
More about Ascelia Pharma AB
Ascelia Pharma is a biotech company specializing in orphan oncology treatments, focusing on developing and commercializing novel drugs that address unmet medical needs. The company is based in Malmö, Sweden, and is publicly traded on Nasdaq Stockholm under the ticker ACE. Its current drug candidates in development are Orviglance and Oncoral.
Average Trading Volume: 1,579,947
Technical Sentiment Signal: Sell
Current Market Cap: SEK363.3M
For an in-depth examination of ACE stock, go to TipRanks’ Overview page.